Secondary efficacy parameters, including lipid and glucose levels and diastolic and systolic blood pressure, were mostly normal at baseline. This contrasts with an earlier, pilot study of weight loss with orlistat in 20 adolescent participants, in which obesity was extremely severe (mean BMI, 44), and obesity-related metabolic risk factors (hypertension, sleep apnea, abnormalities in lipid levels, and glycemic control) were more frequent.29 As such, orlistat generally demonstrated minimal effects on these metabolic risk factors, although it did significantly reduce waist circumference and diastolic blood pressure compared with placebo.